izpis_h1_title_alt

Amide containing NBTI antibacterials with reduced hERG inhibition, retained antimicrobial activity against gram-positive bacteria and in vivo efficacy
ID Kokot, Maja (Author), ID Weiss, Matjaž (Author), ID Zdovc, Irena (Author), ID Senerovic, Lidija (Author), ID Radakovic, Natasa (Author), ID Anderluh, Marko (Author), ID Minovski, Nikola (Author), ID Hrast, Martina (Author)

.pdfPDF - Presentation file, Download (3,61 MB)
MD5: 6FC6ED9BBB3E77C73C3AC851DC40CF97
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S0223523423000752 This link opens in a new window

Abstract
Novel bacterial topoisomerase inhibitors (NBTIs) are new promising antimicrobials for the treatment of multidrug-resistant bacterial infections. In recent years, many new NBTIs have been discovered, however most of them struggle with the same issue - the balance between antibacterial activity and hERG-related toxicity. We started a new campaign by optimizing the previous series of NBTIs, followed by the design and synthesis of a new, amide-containing focused NBTI library to reduce hERG inhibition and maintain antibacterial activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This optimization strategy yielded the lead compound 12 that exhibits potent antibacterial activity against Gram-positive bacteria, reduced hERG inhibition, no cardiotoxicity in zebrafish model, and a favorable in vivo efficacy in a neutropenic murine thigh infection model of MRSA infection.

Language:English
Keywords:NBTIs, DNA gyrase, topoisomerase IV, antibacterials, MRSA, hERG inhibition, in vivo efficacy
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
VF - Veterinary Faculty
Publication status:Published
Publication version:Version of Record
Year:2023
Number of pages:13 str.
Numbering:Vol. 250, art. 115160
PID:20.500.12556/RUL-144295 This link opens in a new window
UDC:615.28
ISSN on article:0223-5234
DOI:10.1016/j.ejmech.2023.115160 This link opens in a new window
COBISS.SI-ID:141418755 This link opens in a new window
Publication date in RUL:13.02.2023
Views:454
Downloads:62
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:European journal of medicinal chemistry
Shortened title:Eur. j. med. chem.
Publisher:Elsevier
ISSN:0223-5234
COBISS.SI-ID:25429760 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:DNA giraza, topoizomeraza IV, antibakterijska zdravila, inhibicija, učinkovitost in vivo, farmacevtska kemija, bakterije

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0017
Name:Modeliranje kemijskih procesov in lastnosti spojin

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Funding programme:Young researchers
Project number:39010

Funder:ARRS - Slovenian Research Agency
Funding programme:Young researchers

Funder:Other - Other funder or multiple funders
Funding programme:National Institute of Chemistry, Proof of Concept NICKI

Funder:Other - Other funder or multiple funders
Funding programme:University of Ljubljana Innovation Fund

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back